{"resourceType": "Group", "meta": {"versionId": "63", "lastUpdated": "2025-02-28T19:28:29.454Z", "profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/exposure-group"]}, "extension": [{"url": "http://hl7.org/fhir/StructureDefinition/artifact-author", "valueContactDetail": {"name": "Computable Publishing\u00ae: MAGIC-to-FEvIR Converter"}}, {"url": "http://hl7.org/fhir/StructureDefinition/artifact-relatedArtifact", "valueRelatedArtifact": {"type": "part-of", "resourceReference": {"type": "Composition", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "MAGIC-5288-j1Wqrn-conversion-report", "assigner": {"display": "Computable Publishing LLC"}}, "display": "MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes"}}}, {"url": "http://hl7.org/fhir/StructureDefinition/artifact-relatedArtifact", "valueRelatedArtifact": {"type": "cite-as", "citation": "GLP-1 RAs Group in Adults with diabetes type 2 with moderate CV risk [Database Entry: FHIR Group Resource]. Contributors: Computable Publishing\u00ae: MAGIC-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236535. Revised 2025-02-28. Available at: https://fevir.net/resources/Group/236535. Computable resource at: https://fevir.net/resources/Group/236535#json."}}], "identifier": [{"type": {"text": "FEvIR Object Identifier", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "ACSN", "display": "Accession ID"}]}, "system": "urn:ietf:rfc:3986", "value": "https://fevir.net/FOI/236535", "assigner": {"display": "Computable Publishing LLC"}}, {"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "MAGIC-5288-j1Wqrn-intervention-group-MAGIC-5288-j1Wqrn-intervention-85390-I-85789", "assigner": {"display": "Computable Publishing LLC"}}], "title": "GLP-1 RAs Group in Adults with diabetes type 2 with moderate CV risk", "status": "active", "description": "Glucagon-Like Peptide-1 (GLP-1) receptor agonists", "useContext": [{"code": {"system": "https://fevir.net/resources/CodeSystem/179423", "code": "evidence-communication", "display": "Evidence Communication"}, "valueCodeableConcept": {"coding": [{"system": "https://fevir.net/resources/CodeSystem/179423", "code": "ExposureGroup", "display": "ExposureGroup"}]}}], "membership": "enumerated", "combinationMethod": "all-of", "characteristic": [{"description": "inclusion in Adults with type 2 diabetes with moderate CV risk", "code": {"text": "Member of"}, "valueReference": {"type": "Group", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "MAGIC-5288-j1Wqrn-population-group-85390-85789", "assigner": {"display": "Computable Publishing LLC"}}, "display": "Adults with type 2 diabetes and established CVD (but no CKD)", "reference": "Group/236533"}, "exclude": false}, {"description": "received GLP-1 RA", "code": {"text": "Exposed to"}, "valueReference": {"type": "Group", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "system": "https://fevir.net/FLI", "value": "MAGIC-5288-j1Wqrn-intervention-85390-I-85789", "assigner": {"display": "Computable Publishing LLC"}}, "display": "Glucagon-Like Peptide-1 (GLP-1) receptor agonists", "reference": "Group/236532"}, "exclude": false}], "url": "https://fevir.net/resources/Group/236535", "id": "236535", "publisher": "Computable Publishing LLC", "copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/", "contact": [{"telecom": [{"system": "email", "value": "support@computablepublishing.com"}]}], "text": {"status": "empty", "div": "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>[No data.]</p></div>"}}